Navigation Links
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Date:11/4/2008

n of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obl
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... July 30, 2015 Flexpoint Ford, a private ... sectors, today announced that it has entered into a ... Stuart to form Kastle Therapeutics, LLC (Kastle).  The ... will focus on acquiring, developing and commercializing pharmaceuticals targeted ... opportunities include select therapies already approved for marketing, as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... Science is largely a collaborative enterprise. Frequently researchers ... pool their efforts and exchange ideas, to devise ... such as those known as autism spectrum disorders, ... on diverse populations of patients, finding a broader ...
... Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease ... Blinded one-year blood pressure (BP) reduction data from the ongoing ... lmesartan A nd D iabetes M icro ... American Society of Hypertension (ASH) Twenty-Fourth Annual Scientific Meeting and ...
Cached Medicine Technology:Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 2Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 3Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 4Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 5Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 6Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 7
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... Angeles, California (PRWEB) , ... July 30, 2015 , ... ... August 5th 2015 - “Learn How to Make Money in the Booming Homecare Business.” ... Los Angeles CA 90010. , The event will be hosted by ...
(Date:7/30/2015)... ... 2015 , ... After conducting a nationwide executive search led by healthcare leadership ... Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed ... leadership experience, Walsh is an expert in organizational change, physician development, implementation of quality ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... with its Medicare administrative contractor (MAC) over submitted claims for bariatric surgery that, ... a challenge to program integrity, Becky Dennis, a nurse auditor at WellSpan Health, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... largest amount of research grants in its history of funding brain aneurysm research. ... who have dedicated their life’s work toward scientific research directed at early detection, ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4
... drugs meant for treating HIV patients also served to protect ... the same can be applied to human beings also has ... ,Rhesus monkeys were experimented upon by the ... them with a version of the Truvada, manufactured by Gilead ...
... older adults due to brain related changes, according to ... easy where younger adults are concerned. The healthy middle ... good where concentrating is concerned, according to functional magnetic ... of the Rotman Research Institute at the Baycrest Center ...
... rates of patients, specific for every surgeon in Scotland has ... community. A majority of the surgeons feel that the ... the surgeon, list of hospitals in which the surgeon has ... the associated mortality rate are amongst the details published. The ...
... that there has been an increase in heart failure cases among ... with men surviving for longer periods. There has been a ... to 1994 period when compared to the 1970 to 1974 period, ... the study. ,The chances of heart failure occurring ...
... National Institute of Immunology are reported to have identified ... the tuberculosis (TB) bacteria survives in the human body. ... more effective medicines to combat the disease, which claims ... annually. The research team led by Rajesh S. Gokhale ...
... A team of researchers led by Dr Stephen Harbarth have ... to be useful in reducing the // infection rates ... by the NHS in dealing with the bug. ... in patient swabs. The researchers said that this test was ...
Cached Medicine News:Health News:The Publication Of Surgeon Specific Death Rates Raises Controversy 2
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: